Results 41 to 50 of about 29,046 (192)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes [PDF]

, 2015
OBJECTIVE: Acute coronary syndrome (ACS) encompasses ST segment elevation myocardial infarction (STEMI), with generally high thrombus burden and non-ST segment elevation ACS (NSTE-ACS), with lower thrombus burden.
Farag, M, Gorog, DA, Prasad, A, Srinivasan, M   +3 more
core   +1 more source

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Fondaparinux sodium has been compared with low‐molecular‐weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis.
Arun Kumar, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, Wenchen Wu   +6 more
doaj   +1 more source

Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline [PDF]

, 2016
The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular & Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to assist physical therapists in their decision-making process when ...
Auten, Beth, Frese, Ethel M., Hillegass, Ellen, Puthoff, Michael, Sobush, Dennis, Thigpen, Mary   +5 more
core   +1 more source

Common Practice in the Treatment of Superficial Vein Thrombosis Involving the Sapheno-Femoral Junction: Results from a National Survey of the Italian Society of Angiology and Vascular Medicine (SIAPAV)

Medicina, 2023
Background and Objectives: Prophylactic doses of low-molecular-weight heparins or fondaparinux showed their efficacy and safety for treatment of all superficial vein thrombosis (SVT) of the lower limbs, yet not for those extended to the last 3 cm of the ...
Giuseppe Camporese, Pierpaolo Di Micco, Marcello Di Nisio, Walter Ageno, Romeo Costanzo Martini, Paolo Prandoni   +5 more
doaj   +1 more source

Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review [PDF]

, 2012
INTRODUCTION: Despite evidence-based guidelines for venous thromboembolism prevention, substantial variability is found in practice. Many economic evaluations of new drugs for thromboembolism prevention do not occur prospectively with efficacy studies ...
Deborah J Cook, Robert A Fowler, Ruxandra Pinto, Subarna Thirugnanam, William H Geerts   +4 more
core   +1 more source

Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

Vascular Health and Risk Management, 2010
François SchieleDepartment of Cardiology, University Hospital Jean-Minjoz, Besançon, FranceAbstract: Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS).
François Schiele
doaj  

Advances in Chemical Synthesis of Fondaparinux

Journal of Chemistry, 2019
Fondaparinux (trade name Arixtra) is a safe and efficacious anticoagulant, and it is chemically related to low-molecular-weight heparins such as enoxaparin. Fondaparinux is a synthetic pentasaccharide, and its synthesis is difficult and expensive.
Yili Ding, Chamakura V. N. S. Vara Prasad, Bingyun Wang   +2 more
doaj   +1 more source

Prevention of venous thromboembolism after hip and knee replacement among older adults [PDF]

, 2017
BACKGROUND: Venous thromboembolism (VTE) after total hip and knee replacement is a major patient safety threat, and pharmacologic prophylaxis is generally recommended. However, clinicians disagree on the optimal prophylaxis agent.
Ko, Darae
core  

Parenteral anticoagulants in the treatment of acute coronary syndrome: what modern clinical guidelines say

Атеротромбоз, 2022
Parenteral administration of high (therapeutic) doses of anticoagulants is a mandatory component of the initial treatment of acute coronary syndrome (ACS) unless contraindicated.
I. S. Yavelov
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source